Clinical trials: Botulinum toxin type A
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Spasticity
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total…
- Trial name
- LANTIMA (NCT04752774)
- Testing
- Corabotase, Dysport
- Where
- 81 sites in United States, Austria and 12 more
- Volunteers
- 240 people
- Sponsor
- Ipsen
Glabellar Lines
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines.
- Trial name
- NCT00512135
- Testing
- IncobotulinumtoxinA (Xeomin) (20 units)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 801 people
- Sponsor
- Merz Pharmaceuticals GmbH
Healthy Volunteers
Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
This study design is a randomized, double-blind, intra-individual controlled, single-center, phase 1 healthy volunteer study. Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will…
- Trial name
- NCT03796351
- Testing
- MT10107, Botox
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Spasticity
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT06150729
- Where
- 8 sites in Mexico
- Volunteers
- 107 people
- Sponsor
- AbbVie
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014635
- Testing
- Botulinum Toxins, Type A
- Where
- 14 sites in United States, Canada
- Volunteers
- 306 people
- Sponsor
- Revance Therapeutics, Inc.
Migraine
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
- Trial name
- NCT04845178
- Testing
- ABP-450
- Where
- 62 sites in United States, Australia and 1 more
- Volunteers
- 797 people
- Sponsor
- AEON Biopharma, Inc.
Cervical Dystonia, Spasmodic Torticollis
Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter, randomized, double-blind, parallel group comparative study by intramuscularly administering to patients with spasmodic torticollis.
- Trial name
- NCT00165776
- Testing
- BOTULINUM TOXIN TYPE B
- Where
- 21 sites in Japan
- Volunteers
- 133 people
- Sponsor
- Eisai Co., Ltd.
Glabellar Frown Lines
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
- Trial name
- NCT05146999
- Testing
- QM1114-DP
- Where
- 9 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Facial Rhytides, Glabellar Rhytides
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines [crow's feet lines]).
- Trial name
- NCT02261493
- Testing
- OnabotulinumtoxinA, Normal Saline
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 787 people
- Sponsor
- Allergan
Postherpetic Neuralgia
A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
4-month study including a 30-day baseline phase
- Trial name
- NCT00168441
- Testing
- Botulinum Toxin Type A
- Volunteers
- 117 people
- Sponsor
- Allergan
Other Infantile Cerebral Palsy
Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy
To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of cerebral palsy in children.
- Trial name
- NCT01787344
- Testing
- Botulinum Toxin Type A(Botox®), Botulinum toxin type A(Botulax®)
- Where
- 6 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Hugel
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Cervical Dystonia
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
The purpose of this study is to evaluate how well a new drug called Dysport NG works and how safe it is, when it is used for the treatment of cervical dystonia. Dysport NG will be compared to an approved drug called Dysport.
- Trial name
- NCT01261611
- Testing
- Botulinum toxin type A
- Where
- 57 sites in Australia, Austria and 9 more
- Volunteers
- 382 people
- Sponsor
- Ipsen
Forehead Lines
A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05152576
- Testing
- OnabotulinumtoxinA X
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan